慢性粒状性疾患における動脈硬化症の評価

Christopher T Sibley¹, Tyra Estwick¹, Anna Zavodni¹

¹From the Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center (C.T.S., A.Z., A.C.K., E.B.T., D.A.B.), Laboratory of Host Defenses (T.E., P.B.S., A.K.R.S., H.L.M., K.A.Z., J.I.G.), Biostatistics Research Branch (C.-Y.H.), and Laboratory of Clinical Infectious Diseases (S.M.H.), National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute (A.T.R.), National Institutes of Health, Bethesda, MD.

Circulation

|September 21, 2014

まとめ

慢性小胞性疾患 (CGD) の患者は,心血管リスク要因にもかかわらず,動脈動脈硬化症が少ない. これはNADPH酸化酵素が動脈硬化症の発達に役割を果たす可能性があることを示唆しています.

科学分野:

心血管研究循環器科の研究
免疫学免疫学とは
メディカルイマージング (医学イメージング)

背景:

慢性粒球性疾患 (CGD) は,NADPH酸化酵素の欠陥による免疫不全を含み,酸化ストレスを潜在的に軽減します.
本研究では,CGDが動脈硬化症の発達に及ぼす影響を調査しています.

研究の目的:

心血管疾患の危険因子,炎症,およびCGD患者のサブクリニック性動脈硬化と対照群を評価する.
CGD,危険因子,動脈硬化症の負担との関係を調査する.

主な方法:

41人のCGD患者と25人の対照群の見通し評価.
頸動脈と冠動脈の動脈硬化を定量化するためにMRIとCTを使用しました.
伝統的な危険因子,炎症マーカー (hs-CRP,oxLDL,HDL) と中性粒子の活性化を分析した.

主要な成果:

CGDの患者は,対照群よりも高血圧,hs-CRP,oxLDL,およびHDLを低くした.
危険因子にもかかわらず,CGD患者には動脈の壁の体積が22%減った (P<0.001).
頸動脈の発見は,CGDサブタイプ全体で一貫しており,リスク要因とは無関係でした.

結論:

リスク要因にもかかわらず,CGD患者の低動脈動脈硬化症は,臨床的に有意な動脈硬化症におけるNADPH酸化酵素の役割に疑問を投げかけています.
心血管疾患におけるNADPH酸化酵素阻害の治療の可能性を調査するために,さらに高解像度の研究が必要である.

キーワード:

動脈硬化症 (動脈動脈硬化症) について頸動脈動脈頸動脈動脈が動いている.冠動脈の血管は,冠動脈の血管である免疫系免疫系免疫系とは炎症炎症炎症炎症

さらに関連する動画

06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.0K

関連する概念動画

01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

838

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

838

01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...

01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

1.3K

01:23

Rheumatic Heart Disease I: Introduction

1.0K

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

1.0K

01:26

Atherosclerosis III: Management

634

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

634

01:30

Atherosclerosis I: Introduction

2.3K

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...